Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679413 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
A Phase 1 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06679413 is a Phase 1 study that has completed, run by UCB Biosciences. The registered enrollment target is 22 participants.
The verdict
NCT06679413, a Phase 1 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008
Interventions
- DRUG metformin
- DRUG midazolam
- DRUG bupropion
- DRUG fenfluramine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2025-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679413
The ClinicalTrials.gov registry entry for NCT06679413 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.
NCT06679413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06679413 about?
NCT06679413 is a clinical study titled "A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants". The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008
What is the current status of trial NCT06679413?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-12-04. Estimated completion is 2025-06-12.
What interventions are being tested in trial NCT06679413?
The interventions under investigation include: metformin (DRUG), midazolam (DRUG), bupropion (DRUG), fenfluramine HCl (DRUG).
Who is sponsoring clinical trial NCT06679413?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.